Proposed pharmacovigilance fees unjustifiably high, says EU generics industry
This article was originally published in SRA
The fees rates proposed by the European Commission for implementing the new pharmacovigilance law are "unjustifiably high" and could result in an average-sized generic medicines company paying €20 million ($26 million) – the highest possible amount – in annual pharmacovigilance fees alone, the European generic medicines industry association, the EGA, has warned1.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.